Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772261 · ClinicalTrials.gov registry record · NA
GEBT Lot-to-Lot and Biological Variability
A NA study, sponsored by Cairn Diagnostics.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT04772261: Completed NA study, sponsored by Cairn Diagnostics.
NCT04772261 is a NA study that has completed, run by Cairn Diagnostics. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04772261, a NA study, has completed, sponsored by Cairn Diagnostics.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information regarding lot-to-lot variability in 13C-Spirulina test meal lets and within-subject biological variability.
Primary Outcome
Participant kPCD values at each measured timepoint from each lot of 13C-Spirulina GEBT test meal will be plotted to compare in vivo results across each lot of material
Interventions
- DIAGNOSTIC_TEST 13C-Spirulina GEBT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2022-01-10 |
| Phase | NA |
What the finished NCT04772261 record still lists
NCT04772261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which 13C-Spirulina GEBT is the first listed.
NCT04772261 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04772261 about?
NCT04772261 is a clinical study titled "GEBT Lot-to-Lot and Biological Variability". The purpose of this study is to collect information regarding lot-to-lot variability in 13C-Spirulina test meal lets and within-subject biological variability.
What is the current status of trial NCT04772261?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2021-02-05. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT04772261?
The interventions under investigation include: 13C-Spirulina GEBT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04772261?
This trial is sponsored by Cairn Diagnostics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04772261's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI